Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection

BACKGROUND: Bevacizumab is commonly used in combination with chemotherapy in the treatment of metastatic colorectal cancer, but to date, despite extensive research, no predictive or prognostic biomarkers for bevacizumab have been identified. The development of bevacizumab-induced arterial hypertensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dewdney, A, Cunningham, D, Barbachano, Y, Chau, I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364119/
https://www.ncbi.nlm.nih.gov/pubmed/22531628
http://dx.doi.org/10.1038/bjc.2012.152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364119/
https://www.ncbi.nlm.nih.gov/pubmed/22531628
http://dx.doi.org/10.1038/bjc.2012.152

Ejemplares similares